Form 8-K - Current report:
SEC Accession No. 0001558370-22-000738
Filing Date
2022-02-03
Accepted
2022-02-03 06:07:47
Documents
18
Period of Report
2022-02-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrxp-20220202x8k.htm   iXBRL 8-K 59842
2 EX-10.1 nrxp-20220202xex10d1.htm EX-10.1 263751
3 EX-10.2 nrxp-20220202xex10d2.htm EX-10.2 139225
4 EX-10.3 nrxp-20220202xex10d3.htm EX-10.3 173744
5 EX-10.4 nrxp-20220202xex10d4.htm EX-10.4 142945
6 EX-99.1 nrxp-20220202xex99d1.htm EX-99.1 12988
  Complete submission text file 0001558370-22-000738.txt   1105749

Data Files

Seq Description Document Type Size
7 EX-101.SCH nrxp-20220202.xsd EX-101.SCH 4468
8 EX-101.DEF nrxp-20220202_def.xml EX-101.DEF 14718
9 EX-101.LAB nrxp-20220202_lab.xml EX-101.LAB 21449
10 EX-101.PRE nrxp-20220202_pre.xml EX-101.PRE 16036
12 EXTRACTED XBRL INSTANCE DOCUMENT nrxp-20220202x8k_htm.xml XML 7387
Mailing Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801
Business Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 22586383
SIC: 2834 Pharmaceutical Preparations